New York, New York (PRWEB) July 25, 2014
A report released by the Juvenile Diabetes Cure Alliance reviews JDRF’s revenue and spending during fiscal year 2013 (July 1, 2012- June 30, 2013).
Outside of the US government’s National Institutes of Health (NIH), the JDRF is the largest single funder of type 1 diabetes research in the world. It has global reach and relationships with most of the top research centers. There is no organization better positioned to deliver a cure for type 1 diabetes in the near future.
Since the 2008 financial crisis, revenue has been steadily increasing. The JDRF has well-honed fundraising operations, and a majority of their annual revenue comes from community building events such as walks and galas. “The JDRF is unique in that a majority of its revenues are generated by small gifts from many donors, rather than very large gifts from a few high net worth individuals,” Phil Shaw, General Manager of the JDCA, said. “Every donor’s voice and intentions matter, but it is even more true for an organization built on walkers, volunteers, and small donors.”
At its peak in 2008, type 1 research grants were 66% of total annual spending. In 2013, this decreased to only 51%; it’s lowest level in 10 years. Furthermore, spending on research grants dropped substantially from $156 million in 2008 to only $106 million in 2013. This is a decline of nearly 30% while all non-research categories increased.
“This trend away from research is worrying,” Shaw said. “We’ve found through regular surveys that the vast majority of donors give with the desire to support cure research. Donors need to be aware of this shift and urge the JDRF to reverse this spending that is not aligned with their priorities and not focused on delivering a cure in the near term.”
To download a copy of the report and explore more information on the major type 1 nonprofits, visit the JDCA website.
About the JDCA
The JDCA is an independent analyst of the type 1 diabetes charitable universe and brings a business-like perspective to help donors focus research toward a practical cure. The mission of the JDCA is to achieve a type 1 practical cure before 2025 by steering donor contributions to the most effective charities.